-
Innovation Ranking
Innovation Ranking – GC Pharma
GC Biopharma Corp (GC Biopharma), formerly known as GC Pharma, a subsidiary of Green Cross Holdings Corp, provides plasma protein therapeutics and vaccines. The company develops, manufactures, and markets a wide product portfolio comprising plasma derivatives including albumin, immunoglobulin, and antithrombin; vaccines for infectious diseases; prescription drugs for treating cardiovascular, respiratory, central nervous system (CNS), gastrointestinal and immunology diseases, musculoskeletal disorders, genetic disorders, metabolic disorders and hematological disorders; and Over-the-counter (OTC) drugs including anti-inflammatory drugs, anti-allergic products, and others. The...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GC-101 in Metastatic Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GC-101 in Metastatic Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GC-101 in Metastatic Melanoma Drug Details: GC-101 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GC-3111A in Pertussis (Whooping Cough)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GC-3111A in Pertussis (Whooping Cough) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GC-3111A in Pertussis (Whooping Cough) Drug Details: GC-3111A is under...
-
Product Insights
NewNet Present Value Model: Gracell Biotechnologies Inc’s GC-012F
Empower your strategies with our Net Present Value Model: Gracell Biotechnologies Inc's GC-012F report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GC-1118A in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GC-1118A in Gastric Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GC-1118A in Gastric Cancer Drug Details: GC-1118A is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GC-3111A in Pertussis (Whooping Cough)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GC-3111A in Pertussis (Whooping Cough) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GC-3111A in Pertussis (Whooping Cough) Drug Details: GC-3111A is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GC-012F in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GC-012F in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GC-012F in Relapsed Multiple Myeloma Drug Details: GC0-12 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GC-012F in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GC-012F in Refractory Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GC-012F in Refractory Multiple Myeloma Drug Details: GC0-12 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AMG-355 in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AMG-355 in Gastric Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AMG-355 in Gastric Cancer Drug Details: AMG-355 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AMG-355 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AMG-355 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AMG-355 in Solid Tumor Drug Details: AMG-355 is under development for...